Life Technologies Introduces the Benchtop Ion Proton™ Sequencer; Designed to Decode a Human Genome in One Day for $1,000 Democratizing DNA sequencing by reducing time, cost and informatics bottleneck
SAN FRANCISCO, Jan. 10, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced it is taking orders for the new benchtop Ion Proton™ Sequencer that is designed to sequence the entire human genome in a day for $1,000.
The Ion Proton™ Sequencer, priced at $149,000, is based on the next generation of semiconductor sequencing technology that has made its predecessor, the Ion Personal Genome Machine™ (PGM™), the fastest-selling sequencer in the world.
Up to now, it has taken weeks or months to sequence a human genome at a cost of $5,000 to $10,000 using optical-based sequencing technologies. The slow pace and the high instrument cost of $500,000 to $750,000 have limited human genome sequencing to relatively few research labs.
Baylor College of Medicine, Yale School of Medicine, and The Broad Institute, have each signed up for multiple Ion Proton™ Sequencers and will be the first customers to adopt this transformative technology.
Breaking the Cost and Time Barrier for Genomic Sequencing
"A genome sequence for $1,000 was a pipe-dream, just a few years ago," said Dr. Richard Gibbs, Director of the Human Genome Sequencing Center, Baylor College of Medicine. "A $1,000 genome in less than one day was not even on the radar, but will transform the clinical applications of sequencing."
"Cost, speed and accuracy are key elements in the use of DNA sequencing for both disease-gene discovery and clinical utility," said Dr. Richard Lifton, Chair of the Department of Genetics, Yale School of Medicine. "The technological advances in the new Ion Proton™ instrument promise to be game-changing for both research and clinical applications."
"We are excited about the paradigm-shifting potential of the new Proton Sequencer, which projects to sequence a human genome in just a few hours with only one run on a single machine," said Dr. Chad Nusbaum, co-director of the Broad Institute's Genome Sequencing and Analysis Program. "The platform's speed and power promise to enable both large-scale research and new clinical applications."
The Power of Benchtop Sequencing for All Applications
Between the benchtop Ion PGM™ Sequencer and the benchtop Ion Proton™ Sequencer, the Ion Torrent technology can cover any application. The Ion PGM™ Sequencer is ideal for sequencing genes, small genomes, panels of genes, or performing gene expression profiling, for as little as $99 a chip. The Ion PGM™ Sequencer's speed, simplicity and scalability also make it an ideal platform to extend into diagnostics. Life Technologies will seek FDA clearance for the Ion PGM™ platform in 2012.
The Ion Proton™ Sequencer is ideal for sequencing both exomes – regions in the DNA that code for protein – and human genomes. The Ion Proton™ I Chip, ideal for sequencing exomes, will be available mid-2012. The Ion Proton™ II Chip, ideal for sequencing whole human genomes, will be available about six months later. In addition, the Ion Proton™ OneTouch™ system automates template prep and a stand-alone Ion Proton™ Torrent Server performs the primary and secondary data analysis.
"Just six months after our first semiconductor sequencing chip was released, people used it to solve the German E. coli outbreak, sequencing the toxic strain in just a couple of hours," said Dr. Jonathan M. Rothberg, the Founder and CEO of the Ion Torrent division. "Now, six months later we're developing a chip that's 1,000 times more powerful than that to sequence an entire human genome in about the same amount of time. That's the power that semiconductors bring to sequencing."
Empowering Every Lab; Freedom from Informatics Bottleneck
The Ion Proton™ Sequencer and Ion Reporter analysis software are designed to analyze a single genome in one day on a stand-alone server – eliminating the informatics bottleneck and high-capital, IT investment associated with optical-based sequencers. The optical-based sequencers require costly IT infrastructure to analyze the large volume of data generated by running batches of six or more genomes at once. The approach drastically slows analysis, which can take weeks to complete and creates the bottleneck in the process.
Simpler Data Interpretation
Another major challenge in whole genome sequencing is the interpretation of the genetic data for use in diagnostic and treatment decisions. To solve this problem, Ion Torrent has sponsored a collaborative effort with Carnegie Mellon University to develop open-source software that will help clinicians interpret and understand genetic data for meaningful application. Ion Torrent is also collaborating with Yale Medical School to identify best practices for diagnostic development and gene discovery as a model for genome sequencing in a clinical setting.
"The huge variation in human genome sequence between individuals has always been an obstacle to understanding how to use sequence information to improve human health," said Dr. Robert F. Murphy, director of the Lane Center for Computational Biology in Carnegie Mellon's School of Computer Science, who will lead the multidisciplinary CMU team. "We believe new machine learning approaches will enable interpretation of personal genome sequences to help doctors diagnose and guide treatment in the near future."
All products referenced are for Research Use Only, and not intended for any animal or human therapeutic or diagnostic use.
About Life Technologies
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Ion Torrent division
SOURCE Life Technologies Corporation